FDA Grants Breakthrough Status to Kowa’s Pemafibrate for PBC Treatment

The designation follows promising results from an ongoing Phase II clinical trial, K-808-2.01, where the drug demonstrated a significant reduction in alkaline phosphatase levels. These findings, unveiled at the European Association for the Study of the Liver Congress in May 2026, suggest that pemafibrate could offer a substantial clinical improvement over existing standards of care. Kowa intends to position the drug as a combination therapy alongside ursodeoxycholic acid for patients with an inadequate response, or as a standalone option for those who cannot tolerate standard treatments.

Primary biliary cholangitis causes progressive inflammation and destruction of the intrahepatic bile ducts, often leading to cirrhosis and liver failure. Pemafibrate works by regulating lipid and glucose metabolism and is expected to mitigate disease progression through the micellization of hydrophobic bile acids and anti-inflammatory activation of the PPARα nuclear receptor. Kowa, which already markets the compound as Parmodia Tablets for hyperlipidemia in Japan, is now steering the drug toward global approval to address the severe fatigue and pruritus associated with this rare condition.